medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2011, Number 1

<< Back Next >>

Residente 2011; 6 (1)

Manifestaciones clínicas reumáticas y marcadores de autoinmunidad en pacientes con infección por virus de hepatitis C

Rojo J, Trujillo X, Bellaney CG, Chávez EL, Barroso P, Olague G, Ornelas S, Nava A, Gámez-Nava JI, Salazar-Páramo M

Language: Spanish
References: 31
Page: 32-37
PDF size: 246.91 Kb.


ABSTRACT

Introduction: Infection with hepatitis C virus (HCV) is associated with a wide spectrum of extrahepatic manifestations which include those related to systemic autoimmune rheumatic diseases. Objective: To describe the clinical manifestations of rheumatic and autoimmune markers in patients with HCV infection. Patients and methods: Descriptive cross-sectional. We evaluated patients diagnosed with HCV infection. A questionnaire was applied based on clinical criteria of the American College of Rheumatology for the diagnosis of rheumatoid arthritis, lupus and scleroderma. Descriptive statistics were used and χ2 and/or Fisher’s exact test. Results: We studied 95 patients (49 women and 46 men). The average age was 47.1 years. Clinical data: arthralgia and myalgia (55%), blood disorders (13%), xerophthalmia (5%), xerostomia (5%), arthritis (4%), oral ulcers (4%), photosensitivity (3%) malar rash (2%). Ninety serologic tests were conducted, of which rheumatoid factor was found positive in 15% and antinuclear antibodies in 33%. Conclusions: The results suggest that rheumatic symptoms and autoimmune markers are common in patients with HCV infection and these should not be dismissed in their evaluation.


REFERENCES

  1. Simons JN, Leary TP, Dawson GJ. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1995; 1: 564-569.

  2. Shimizu YK, Feinstone SM, Kohara M. Hepatitis C virus detection of intracellular virus particles by electron microscopy. Hepatology 1996; 23: 205-209.

  3. Grakoui A, Wychawski C, Lin C. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993; 67: 1385-1395.

  4. Lin C, Lindenbach BD, Pragai BM. Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2 specific products with different C termini. J Virol 1996; 69: 7461-7471.

  5. Pileri P, Vematsu Y, Campagnoli S. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-941.

  6. Duskeiko GM, Scmilovitz-Weiss H, Brown D. Hepatitis C virus genotypes and investigations of type specific differences in geographic origin and disease. J Hepatology 1994; 19: 14-18.

  7. Memon MI, Memon MA. Hepatitis C: An epidemiological review. J Viral Hepat 2002; 9: 84-100.

  8. Alter MJ, Kruszon-Moran D, Nainan OV. The prevalence of hepatitis C virus infection in the United States. N Engl J Med 1999; 341: 556-562.

  9. Alter MJ, Hunit YFJ, Armstrong GL. Epidemiology of hepatitis C. Academic Press 2000: 169-183.

  10. Alter MJ. Epidemiology of hepatitis C in the West. Sem Liv Dis 1995; 15: 5-14.

  11. Pawlotsky JM. Use and interpretation of virologic test. Management of hepatitis C. Consensus Development Conference Update.

  12. Aach RD, Stevens CE. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first and second generation assay. N Engl J Med 1991; 325: 1325-1329.

  13. Findor JA, Frider B. Prevalence of antibodies to hepatitis C virus by second generation enzyme immunoassay in hemodialysis units. Proceedings of the International Symposium on Viral Hepatitis And Liver Disease. Tokyo 1993: 228.

  14. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus non structural protein NS3 transforms NIH 3T3 cells. J Virol 1995; 69: 3893-3896.

  15. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: 35-46.

  16. Fattovich G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow up study of 384 patients. Gastroenterology 1997; 112: 463-472.

  17. Tran A, Quaranta JF, Benzaken S. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993; 18: 253-257.

  18. Ramos-Casals, Front J, Ingelmo M. Prevalencia y significado clínico por el virus de la hepatitis C en las enfermedades autoinmunitarias sistémicas. Med Clin (Barc) 2001; 116: 701-709.

  19. Barbosa VS, daSilva NA, Martins RMB. Hepatitis C virus seroprevalence and genotypes in patients with diffuse connective tissue diseases and spondyloarthropathies. Braz J Med Biol Res 2005; 38: 801-805.

  20. García-Carrasco M, Ramos M. Hepatitis C virus infection in primary Sjögren’s arthritis: prevalence and clinical significance in a serie of 90 patients. Ann Rheum Dis 1997; 56: 173-175.

  21. Hahn BH. Lupus eritematoso sistémico 2002; 2247-2254.

  22. Cacoub P, Renou C, Rosenthal E, Cohen P. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine (Baltimore) 2000; 79: 47-56.

  23. Hahn JA, Page-Shafer K. Hepatitis C virus infection and leedle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34: 180-187.

  24. Arnet FC, Edworthy SM, Bloch DA. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arth Rheum 1998; 31: 315-324.

  25. Cacoub P, Poynard T, Ghillani P, Charlotte F. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 2000; 42: 2204-2212.

  26. Buskila D, Shnaider A, Neumann L. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum 1998; 28: 107-13.

  27. Ramos Casals M, Loustaud-Ratti V. Sjögren syndrome associated with hepatitis C. Medicine (Baltimore) 2005; 84: 81-89.

  28. Bayraktar Y, Bayraktar M, Gurakar A. A comparison of the prevalence of autoantibodies in individual with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune disease. Hepatogastroenterology 1997; 44: 417-25.

  29. Jablonska J, Zabek J, Kozlowaska, J. Immunological disorders in patients with chronic viral hepatitis type C. Przegl Epidemiol 2001; 55: 459-64.

  30. Dehesa VM, Núñez NR. Epidemiology of hepatitis virus B and C. Arch Med Res 2007; 38: 606-11.

  31. Ramos CM. Manifestaciones extrahepáticas en pacientes con infección crónica por el virus de la hepatitis C. Reumatol Clin 2009; 5: 71-75.




2020     |     www.medigraphic.com